The EMA officially vacates its London HQ — next stop Amsterdam; CHMP backs approval of 8 drugs

→ The EMA officially said goodbye to its Canary Wharf headquarters in London on Friday, to set up shop in Amsterdam — a decision triggered by Britain’s 2016 decision to leave the EU.

→ The EU regulator also issued positive recommendations for a slate of treatments, listed below:

These recommendations followed two others from Thursday:

→ Under fire from Starboard and Wellington — which have made their opposition against the $74 billion buyout of Celgene $CELG abundantly clear — Bristol-Myers $BMY has been trying to shore up investor support behind-the-scenes, CNBC reported on Friday. The report suggested Bristol had sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, citing a person briefed on the meetings.

→  UK-based AdoRx Therapeutics has tied up with J&J $JNJ to develop lung cancer drugs in a deal with undisclosed financial terms.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->